New eye drops could replace reading glasses for presbyopia

NCT ID NCT05728944

Completed Symptom relief Sponsor: LENZ Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested LNZ101 eye drops in 229 people aged 45-75 with presbyopia, a condition that makes it hard to see up close. The drops combine aceclidine and brimonidine to temporarily improve near vision. The main goal was to see if participants could read three lines better on an eye chart without losing distance vision. The study is complete, offering hope for a non-surgical option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aceclidine and brimonidine combination eye drops
What this could lead to: If it works, this could offer a non-surgical, temporary fix for reading vision in people with presbyopia.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to everyone. The effect is temporary and requires repeated use. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EYE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder myopia presbyopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EYE DISEASES NEAR VISION PRESBYOPIA REFRACTIVE ERROR

Contacts and locations

Locations

Site #203

Newport Beach, California, 92663, United States
Site #204

Danbury, Connecticut, 06810, United States
Site #205

Crystal River, Florida, 34429, United States
Site #207

Powell, Ohio, 43065, United States
Site #208

St Louis, Missouri, 63128, United States
Site #209

Dothan, Alabama, 36301, United States
Site #211

Louisville, Kentucky, 40206, United States
Site #212

West Fargo, North Dakota, 58078, United States
Site #213

Eugene, Oregon, 97401, United States
Site #214

La Jolla, California, 92037, United States
Site #215

Bozeman, Montana, 59718, United States
Site #216

Scottsdale, Arizona, 85260, United States
Site #217

Warwick, Rhode Island, 02888, United States
Site #218

Northbrook, Illinois, 60062, United States
Site #219

Dover, New Jersey, 07801, United States
Site #220

Glendale, California, 91204, United States
Site #221

Rochester, New York, 14626, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.